Phathom Pharmaceuticals Inc
PHAT
Get informed when a big investor buys or sells
+ FollowMarket Cap$605.14M
Close$
$-4.09
156.1% downside
Current Fair Value
156.1% downsideOvervalued by 156.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $605.14 Million |
|---|---|
| Enterprise Value | $425.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.03 |
| Beta | 0.51 |
| Outstanding Shares | 83,747,104 |
Return
| Return on Equity | -58.12% |
|---|---|
| Return on Assets | 61.18% |
| Return on Invested Capital | 164.57% |
Valuation & Multiples
| P/E Ratio | -5.84 |
|---|---|
| PEG | 5.84 |
| Price to Sales | 3.65 |
| Price to Book Ratio | -1.46 |
| Enterprise Value to Revenue | 1.77 |
| Enterprise Value to EBIT | 1.49 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$73.45 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$85.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1351▲ 7.74% |
|---|---|
| Total Calls | 921,300▼ 12.08% |
| Total Puts | 124,500▲ 105.79% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.56%▲ 2.60% |
|---|---|
| Total Invested | $786.62M▲ 2.76% |
| Investors Holding | 173▼ 6.00% |
ESG Score
No data
About Phathom Pharmaceuticals Inc
55 employeesPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, E...